Antimetabolites in ocular surface neoplasia

Curr Opin Ophthalmol. 1998 Aug;9(4):35-9. doi: 10.1097/00055735-199808000-00006.


Malignant neoplasms of the ocular surface are uncommon but consist of squamous and melanocytic tumors. Surgical excision has been the mainstay of treatment and is perhaps the "gold standard." However, in those circumstances in which surgical intervention is not feasible, adjunctive treatments have been advocated. Recent attention has been given to the use of mitomycin C and 5-fluorouracil for the treatment of ocular surface squamous neoplasia. This article reviews the major publications relating to the use of antimetabolites in ocular surface neoplasia and highlights the most recent contributions to the ophthalmic literature.

Publication types

  • Review

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Carcinoma in Situ / drug therapy*
  • Carcinoma in Situ / pathology
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology
  • Conjunctival Neoplasms / drug therapy*
  • Conjunctival Neoplasms / pathology
  • Corneal Diseases / drug therapy*
  • Corneal Diseases / pathology
  • Eye Neoplasms / drug therapy*
  • Eye Neoplasms / pathology
  • Humans
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Ophthalmic Solutions
  • Treatment Outcome


  • Antimetabolites, Antineoplastic
  • Ophthalmic Solutions